BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1433@pharmaconomics
DTSTAMP:20260707T033905Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:IFRX Approval — vilobelimab
DESCRIPTION:A final FDA approval decision on vilobelimab for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) is expected Jun 30\, 2026.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1708688/000114036126026933/ef20077063_ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/1433
URL:https://pharmaconomics.com/e/1433
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IFRX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR